Patents Assigned to Intercell AG
-
Patent number: 8361476Abstract: The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independantly one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for the preparation of an adjuvant for enhancing the immune response to at least one antigen.Type: GrantFiled: October 18, 2001Date of Patent: January 29, 2013Assignee: Intercell AGInventors: Jörg Fritz, Frank Mattner, Wolfgang Zauner, Eszter Nagy, Michael Buschle
-
Publication number: 20130011403Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: ApplicationFiled: July 6, 2012Publication date: January 10, 2013Applicant: Intercell AGInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
-
Patent number: 8349336Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pyogenes, methods for isolating such antigens and specific uses therefor.Type: GrantFiled: December 18, 2009Date of Patent: January 8, 2013Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Birgit Winkler, Dieter Gelbmann
-
Patent number: 8343510Abstract: The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae (S. agalactiae) or functionally active variant thereof; a protective peptide against S. agalactiae; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S.Type: GrantFiled: January 10, 2008Date of Patent: January 1, 2013Assignee: Intercell AGInventors: Beatrice Senn, Eszter Nagy, Andreas Meinke, Alexander Von Gabain, Barbara Maierhofer, Ulrike Stierschneider, Manfred Berger, Christina Neubauer, Katherine Cohen
-
Publication number: 20120308618Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: ApplicationFiled: February 21, 2011Publication date: December 6, 2012Applicant: Intercell AGInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
-
Patent number: 8323660Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation,—identifying antigens which bind in said screening to antibodies in said antibody preparation,—screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogenType: GrantFiled: August 9, 2010Date of Patent: December 4, 2012Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitre Tempelmaier, Claire M. Fraser, Steven Gill
-
Patent number: 8318908Abstract: The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence is selected from the group comprising SEQ ID NO 11 to SEQ ID NO 20, and the use of such polypeptide for the manufacture of a vaccine.Type: GrantFiled: May 24, 2011Date of Patent: November 27, 2012Assignee: Intercell AGInventors: Dieter J. Reinscheid, Heike Boisvert, Axel Schubert, Bernhard J. Eikmanns, Andreas Meinke
-
Publication number: 20120294881Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.Type: ApplicationFiled: August 3, 2012Publication date: November 22, 2012Applicant: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Tschanun, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing-Kröll, Alexander Von Gabain
-
Patent number: 8303961Abstract: The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.Type: GrantFiled: March 2, 2012Date of Patent: November 6, 2012Assignee: Intercell AGInventors: Urban Lundberg, Andreas Meinke, Eszter Nagy, Alexander Von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska
-
Publication number: 20120269843Abstract: Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.Type: ApplicationFiled: July 3, 2012Publication date: October 25, 2012Applicant: Intercell AGInventors: Andreas Meinke, Duc Min Bui, Eszter Nagy
-
Patent number: 8277815Abstract: The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.Type: GrantFiled: May 18, 2011Date of Patent: October 2, 2012Assignee: Intercell AGInventors: Michael Buschle, Julia-Kristina Fleitmann, Frank Mattner, Jack Melling
-
Patent number: 8241643Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.Type: GrantFiled: March 17, 2009Date of Patent: August 14, 2012Assignee: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Senn, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing-Krōll, Alexander Von Gabain
-
Patent number: 8236326Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection.Type: GrantFiled: April 29, 2008Date of Patent: August 7, 2012Assignee: Intercell AGInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
-
Patent number: 8236325Abstract: Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.Type: GrantFiled: November 24, 2009Date of Patent: August 7, 2012Assignee: Intercell AGInventors: Andreas Meinke, Duc Min Bui, Eszter Nagy
-
Publication number: 20120184710Abstract: The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.Type: ApplicationFiled: March 2, 2012Publication date: July 19, 2012Applicant: INTERCELL AGInventors: URBAN LUNDBERG, ANDREAS MEINKE, ESZTER NAGY, ALEXANDER VON GABAIN, BIRGIT NOIGES, DIETER GELBMANN, ALBINA POLJAK, CHRISTINE TRISKA
-
Publication number: 20120141487Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a Moraxella catarrhalis (Meat) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Moraxella catarrhalis species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell which expresses such antigen. More specifically, such antigens are produced by or associated with bacterial infections caused by Moraxella catarrhalis.Type: ApplicationFiled: May 28, 2010Publication date: June 7, 2012Applicant: Intercell AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Julia Flor, Birgit Noiges, Wolfgang Schueler, Ulrike Schirmer, Verena Salletmayer, Mario Aistleithner, Stefan Seidel, Martin Oleksiewicz
-
Publication number: 20120082674Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.Type: ApplicationFiled: December 12, 2011Publication date: April 5, 2012Applicant: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
-
Patent number: 8129165Abstract: The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from Borrelia species, proteins which are preferably hyperimmune serum reactive antigens, hyperimmune serum reactive antigens, antigens, a process for producing such proteins, hyperimmune serum reactive antigens or antigens, a process for producing a cell which expresses such protein, hyperimmune serum reactive antigen or antigen, an antibody binding to such protein, hyperimmune serum reactive antigen or antigen, a hybridoma cell producing such antibody, methods for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody, the use of such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibodType: GrantFiled: September 14, 2007Date of Patent: March 6, 2012Assignee: Intercell AGInventors: Urban Lundberg, Andreas Meinke, Eszter Nagy, Alexander von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska
-
Publication number: 20120045457Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.Type: ApplicationFiled: February 15, 2010Publication date: February 23, 2012Applicant: INTERCELL AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz
-
Publication number: 20110300169Abstract: The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.Type: ApplicationFiled: May 18, 2011Publication date: December 8, 2011Applicant: INTERCELL AGInventors: JULIA-KRISTINA FLEITMANN, FRANK MATTNER, MICHAEL BUSCHLE, JACK MELLING